Gowling WLG advised AstraZeneca on exclusive option and global license agreement with Pinetree Therapeutics. AstraZeneca has entered into an exclusive option and global license agreement with...
AstraZeneca’s $545m Deal with Pinetree for EGFR Degrader
Eloxx Pharmaceuticals’ Exclusive Licencing Agreement with Almirall
Gowling WLG advised Eloxx Pharmaceuticals on a licence agreement. Eloxx Pharmaceuticals, a company engaged in the science of ribosome modulation, has recently entered into an exclusive...
Sosei Heptares’ Partnership with Boehringer Ingelheim
Gowling WLG advised Sosei Heptares on a multi-million pound drug with Boehringer Ingleheim. Sosei Heptares, a leading biopharmaceutical company, has joined forces with Boehringer Ingelheim in...
AstraZeneca’s Collaboration with Quell Therapeutics
Gowling WLG advised AstraZeneca on the agreement. Cooley LLP advised Quell Therapeutics. A collaboration and license agreement has been established between AstraZeneca and biopharmaceutical company Quell...
Nanexa’s Exclusivity and Evaluation Agreement With Novo Nordisk A/S
Gowling WLG advised Nanexa on the deal. The transaction involved a material transfer and feasibility study agreement with global pharmaceutical company Novo Nordisk A/S. The deal facilitates...
Sosei Heptares’ License Agreement With Eli Lilly
Gowling WLG advised Sosei Heptares. Sosei Heptares signed a collaboration and license agreement with Eli Lilly to develop new treatments in diabetes and metabolic diseases. The...
Oxford BioTherapeutics’ Global Commercial License Agreement
Gowling WLG advised Oxford BioTherapeutics on the deal. Oxford BioTherapeutics on a global commercial license agreement with a biotech company to advance the development of a...
Oxford BioTherapeutics’ Global Commercial License Agreement
Gowling WLG advised Oxford BioTherapeutics on the deal. Oxford BioTherapeutics on a global commercial license agreement with a biotech company to advance the development of a...
Oxford BioTherapeutics’ Collaboration With ImmunoGen, Inc.
Gowling WLG advised Oxford BioTherapeutics on the deal. Ropes & Gray advised ImmunoGen on this new collaboration. Oxford BioTherapeutics on a multi-year collaboration with ImmunoGen, Inc....
Amphista Theraperutics’ Collaboration and License Agreement With Bristol Myers Squibb
Gowling WLG has advised Amphista Theraperutics on the deal. Baker Mackenzie advised Bristol Myers Squibb. The deal is a strategic collaboration and license agreement with Bristol...
Amphista Theraperutics’ Collaboration and License Agreement With Merck Healthcare
Gowling WLG has advised Amphista Theraperutics on the deal. The deal concerns an agreement with Merck Healthcare to collaborate in developing novel protein degrading therapeutics in...
Immedica Pharma AB’s Licence and Supply Agreement With Actinium Pharmaceuticals, Inc
Gowling WLG advised Swedish pharmaceutical company Immedica Pharma AB on the deal. Immedica signed a licence and supply agreement with Actinium Pharmaceuticals, Inc to commercialise Iomab-B, an...